Publications by authors named "Vincent P DiMondi"
Ann Pharmacother
August 2018
Article Synopsis
- The study highlights that a significant number of patients receiving direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) experienced drug-drug interactions (DDIs), with 80.3% having at least one DDI.
- Most of these interactions were either clinically significant or critical, primarily involving acid suppression medications.
- The involvement of a clinical pharmacist was crucial in identifying these interactions and suggesting interventions, ultimately showing no negative impact on treatment efficacy measured by sustained virological response (SVR12).
